13D Filing: OrbiMed Advisors and Clementia Pharmaceuticals Inc (CMTA)

Page 9 of 12

Page 9 of 12 – SEC Filing

OPI IV’s demand and piggyback registration rights described above generally will terminate upon the earlier of: (i) the date five years following the Issuer’s initial public offering or (ii) such time as there are no more Registrable Securities (as defined in the Registration Rights Agreement) outstanding.
The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Registration Rights Agreement, a copy of which is filed as Exhibit 3 and incorporated herein by reference.
Other than as described in this Amendment No. 1, to the best of the Reporting Persons’ knowledge, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer.
Item 7.
Materials to Be Filed as Exhibits
Exhibit
Description
1.
Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital GP IV LLC and Samuel D. Isaly.
2.
Form of Lock-Up Agreement (incorporated by reference to Exhibit A of Exhibit 1.1 to Amendment No. 1 to the Issuer’s Registration Statement on Form F-1 (SEC 333-219066), filed with the SEC on July 21, 2017).
3.
Second Amended and Restated Registration Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated March 16, 2017 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form F-1 (SEC File No. 333-219066), filed with the SEC on June 30, 2017).

Follow Clementia Pharmaceuticals Inc.

Page 9 of 12